ab Augusto Ticker MARINUS

buran und MfG

Datum Erster Hoch Tief Schluss     Stücke Volumen
  08.08.14      8,00      8,04§8,00 8,02 $ 17.500 140 T

GrB

Buch dazu
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

Preis pro share 8,02 $ Schleife 200 spread 0,25% buran und MfG und ticker schei

Nasdaq Buch
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

Börsenbucheinsicht
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

Preis pro Sternchen 8,04 $ Schleife 200 spread 0,50% buran und MfG und Himmel Mond und Sterne wir haben Ticker Sternchen Laternen allzu gerne ..::hopshops HALLO

::::::::::::::::::::: 8,05 $ +0,37% +0,03 $
In Euro: 6,0236 € | Nasdaq, 11.08.14::::::::::::::::: HEISS

www.marinuspharma.com

buran und MfG

Börsenbucheinsicht
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

Preis pro oooh cheri cheri 8,05 $ Schleife 4.500 spread 0,63% buran und MfG und oooooooh cheri cheri ..::hopshops HALLO

Buch dazu
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

Börsenbucheinsicht
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

Preis pro MARINUS 8,02 $ Schleife 100 spread 0,25% buran und MfG und Ticker Dir Ein ..::hopshops HALLO

www.marinuspharma.com/#!contact-us/c1sd2 GrB

$ 8.00 -0.08 (0.93%)
Day High: 8.08
Day Low:  8.00
Volume:    8,000 3:59 PM ET on
Aug 13, 2014
www.marinuspharma.com/#!investors/c242w

www.marinuspharma.com/#!investors/c242w GrB

www.marinuspharma.com/#!investors/c242w GrB

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: Edward F. Smith

        Vice President, CFO, Secretary and Treasurer

        Marinus Pharmaceuticals, Inc.

        (203) 315-0566

        esmith@marinuspharma.com
ir.marinuspharma.com/releasedetail.cfm?ReleaseID=863384

MARINUS PHARMACEUTICALS, INC. ENTERS INTO USE AGREEMENT WITH CYDEX PHARMACEUTICALS, INC. FOR USE OF CAPTISOL(R) FOR GANAXOLONE IVir.marinuspharma.com/releasedetail.cfm?ReleaseID=865715

- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has entered into an agreement with CyDex Pharmaceuticals, Inc., a wholly owned subsidiary of Ligand Pharmaceutical Incorporated, for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous (IV) dose form of ganaxolone with Captisol.ir.marinuspharma.com/releasedetail.cfm?ReleaseID=865715

step towards optimizing our IV formulation of ganaxolone for inpatient, acute care treatment situations," said Christopher M. Cashman, President and CEO of Marinus Pharmaceuticals, Inc. "Ganaxolone IV is planned to be available for human clinical testing next year and complements our existing capsule and liquid suspension dose forms presently in the clinic."ir.marinuspharma.com/releasedetail.cfm?ReleaseID=865715

is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and has been designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and plans to initiate a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABAA receptors. For additional information, please visit the Company's website at www.marinuspharma.com.ir.marinuspharma.com/...ReleaseID=865715

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding our development plans for our product candidate, including optimizing a product's formulation and the clinical trial testing schedule. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters, including the development of formulations of ganaxolone, that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission. ir.marinuspharma.com/releasedetail.cfm?ReleaseID=865715          

www.marinuspharma.com/#!stock-information/c7pm GrB

www.marinuspharma.com/#!financials--filings/c11nn GrB

www.marinuspharma.com/#!corporate-governance/c1e66 GrB

a clinical stage biopharmaceutical company focused on developing and commercializing innovative neuropsychiatric therapeutics. Our clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, an endogenous neurosteroid produced in the central nervous system that modulates the brain neurotransmitter gamma-aminobutyric acid, or GABA. Our lead indication for ganaxolone is as an adjunctive therapy for the treatment of focal, onset seizures in adults with epilepsy... By targeting the same spectrum of GABAA receptors as endogenous allopregnanolone, ganaxolone delivers its therapeutic benefit through a natural mechanism that we believe offers safety and efficacy advantages compared to other marketed antiepileptic medications.www.marinuspharma.com/#!investors/c242w

in a randomized adequate and well-controlled clinical trial for ganaxolone in epilepsy. We expect data from this trial in the second half of 2015. In addition, we believe ganaxolone has potential in a broad range of neuropsychiatric disorders, including orphan indications. We currently have a proof-of-concept Phase 2 clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome, or FXS, an orphan indication in which GABA activity has been implicated in the expression of the disorder. We plan to pursue other potential indications related to our mechanism when non-dilutive opportunities arise.www.marinuspharma.com/#!investors/c242w

Buch dazu
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

Preis pro Schüssel 8,08 $ Schleife 1.000 spread 1,00% buran und MfG und datt mich datt hier je schüss schüss schüsselt wird ..::hopshops HALLO

Zeit    Kurs Stück
  15:30:02§8,01 $ 100
__________________
GRATULATION

Buch dazu
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof

Kosmonova buran

Kosmonova buran

Prozess der börsentäglichen Bewertung offener Positionen zur Feststellung von Gewinnen und Verlusten aufgrund der Kursentwicklung von Kontrakten. Siehe auch: Variation Margin http://www.ariva.de/extras/lexikon.m?begriff=Mark_to_Market_Methode

Datum Erster Hoch Tief Schluss     Stücke Volumen
  13.02.15     11,09     11,09§10,72 10,94 $ 13.523 148 T

GrB

..yöah

::::::: 10,00 $ ,GrB

Zelle noch intakt ?

Buch
http://www.ariva.de/marinus_pharmaceut-aktie/...nd_sales?boerse_id=40 GrB

Aktien New York: Dow verliert nach Dollar-Anstieg und Ölpreis-Verfall
18:51 19.03.15 http://www.ariva.de/news/...llar-Anstieg-und-Oelpreis-Verfall-5315545

Datum Erster Hoch Tief Schluss     Stücke Volumen
  15.06.15     12,72     12,81§12,19 12,22 $ 64.094 0,80 M

GrB

http://www.ariva.de/marinus_pharmac.-aktie/kurs GrB

Buch
http://www.ariva.de/marinus_pharmac.-aktie/..._and_sales?boerse_id=40 GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  21.08.15     13,61     13,87§12,97 13,62 $ 42.200 0,56 M

GrB

Datum Erster Hoch Tief Schluss Stücke Volumen
  13.11.15      5,40      5,70§5,38 5,38 $ 310.015 1,65 M

GrB

Datum Erster Hoch Tief Schluss Stücke Volumen
  10.02.16      4,50      4,62§4,30 4,38 $ 103.104 431 T

GrB

Preis pro Schein 4,678 € Schleife 3.000 spread 3,96% buran und MfG olee olee

Datum Erster Hoch Tief Schluss Stücke Volumen
  01.07.16      1,26      1,32§1,25 1,32 $ 194.526 250 T

GrB

Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference
Mar 15, 2017 www.marinuspharma.com/

www.bioportfolio.com/resources/trial/...partum-Depression.html

clinicaltrials.gov/ct2/show/...naxolone&draw=1&rank=4

Preis pro Schein 2,08 $ Schleife 2.300 spread 1,46% buran und MfG olee olee

Die 5K mit denen ich seit 26.7. drin bin einfach laufen lassen :)))  

Provides Business Update and Reports Third Quarter 2017 Financial Results
Oct 31, 2017 www.marinuspharma.com/